Ocrelizumab in Breastmilk

Summary

Ocrelizumab in Breastmilk is a clinical trial^[1].

Key Facts

• Ocrelizumab in Breastmilk is in the country of United States^[2].
• Ocrelizumab in Breastmilk's instance of is recorded as clinical trial^[3].
• Ocrelizumab in Breastmilk's start time is recorded as +2020-06-19T00:00:00Z^[4].
• Ocrelizumab in Breastmilk's end time is recorded as +2021-07-19T00:00:00Z^[5].
• Ocrelizumab in Breastmilk's contributor to the creative work or subject is recorded as Genentech^[6].
• Ocrelizumab in Breastmilk's sponsor is recorded as University of California, San Francisco^[7].
• Ocrelizumab in Breastmilk's main subject is recorded as multiple sclerosis^[8].
• Ocrelizumab in Breastmilk's number of participants is recorded as {'unit': '1', 'amount': '+20'}^[9].
• Ocrelizumab in Breastmilk's title is recorded as Monoclonal Antibodies in Mothers' Milk and Infants: Ocrelizumab in Breastmilk^[10].
• Ocrelizumab in Breastmilk's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[11].
• Ocrelizumab in Breastmilk's ClinicalTrials.gov ID is recorded as NCT04387110^[12].
• Ocrelizumab in Breastmilk's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+64'}^[13].
• Ocrelizumab in Breastmilk's research intervention is recorded as ocrelizumab^[14].
• Ocrelizumab in Breastmilk's research subject recruitment status is recorded as not yet recruiting^[15].
• Ocrelizumab in Breastmilk's study type is recorded as observational study^[16].